EUDAW Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeValuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- —
- P/S (TTM)
- —
- EV/EBITDA
- —
Profitability & growth
- ROE (TTM)
- 0.0%
- Operating margin
- -37.0%
- Revenue growth YoY
- 60.2%
- Dividend yield
- —
- Beta
- 0.16
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About EUDA Health Holdings Limited
Company profileEUDA Health Holdings Limited is a dynamic biotechnology firm committed to developing cutting-edge therapies targeting dermatological and chronic health conditions. The company emphasizes scientific excellence and the integration of advanced technologies to address critical unmet medical needs, supported by a strategically prioritized pipeline of innovative products. With a seasoned leadership team focused on enhancing patient outcomes, EUDA is well-positioned to capitalize on growth opportunities in the evolving healthcare landscape.
Classification
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 60 KAKI BUKIT PLACE, SINGAPORE, SINGAPORE
- Fiscal year end
- December
- Latest quarter
- Sep 30, 2025
Educational content · Not investment advice or recommendations
We're educators, not advisors. Your decisions are your own. Disclaimer
I'm your AI thinking companion for the markets — I can help you explore and learn, but I'm not a financial advisor. Everything here is educational. Disclaimer